Cogent Biosciences, Inc. Investing Cash Flow
Cogent Biosciences, Inc. (COGT) reported Investing Cash Flow of -$22.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-10
- Cogent Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $14.28M, a 60.27% increase year-over-year.
- Cogent Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$36.46M, a 152.55% decline year-over-year.
- Cogent Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$322.77M, a 623.37% decline year-over-year.
- Cogent Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$155.05M, a 357.61% decline year-over-year.
- Cogent Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$399.53M, a 1143.80% decline from fiscal 2024.
- Cogent Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2024 was $38.28M.
- Cogent Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$97.82M.
- Cogent Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$124.72M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$22.18M 10-Q · filed 2026-08-10 | -$344.95M derived: sum of 3 quarters · filed 2026-08-10 | -$499.99M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$36.46M 10-Q · filed 2026-05-05 | -$359.23M derived: sum of 2 quarters · filed 2026-05-05 | -$514.27M derived: sum of 3 quarters · filed 2026-05-05 | -$505.36M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$322.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$477.81M derived: sum of 2 quarters · filed 2026-02-17 | -$468.90M derived: sum of 3 quarters · filed 2026-08-10 | -$399.53M 10-K · filed 2026-02-17 |
| 2025-09-30 | -$155.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$146.14M derived: sum of 2 quarters · filed 2026-08-10 | -$76.76M 10-Q · filed 2025-11-07 | -$15.09M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $8.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $78.29M 10-Q · filed 2026-08-10 | $139.96M derived: sum of 3 quarters · filed 2026-08-10 | $200.15M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $69.38M 10-Q · filed 2026-05-05 | $131.05M derived: sum of 2 quarters · filed 2026-05-05 | $191.24M derived: sum of 3 quarters · filed 2026-05-05 | $106.61M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $61.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $121.86M derived: sum of 2 quarters · filed 2026-02-17 | $37.23M derived: sum of 3 quarters · filed 2026-02-17 | $38.28M 10-K · filed 2026-02-17 |
| 2024-09-30 | $60.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$24.44M derived: sum of 2 quarters · filed 2025-11-07 | -$23.39M 10-Q · filed 2025-11-07 | -$12.91M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | -$84.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$83.58M 10-Q · filed 2025-08-05 | -$73.09M derived: sum of 3 quarters · filed 2026-02-17 | -$163.63M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $1.04M 10-Q · filed 2025-05-06 | $11.53M derived: sum of 2 quarters · filed 2026-02-17 | -$79.00M derived: sum of 3 quarters · filed 2026-02-17 | -$156.66M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $10.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$80.05M derived: sum of 2 quarters · filed 2026-02-17 | -$157.71M derived: sum of 3 quarters · filed 2026-02-17 | -$97.82M 10-K · filed 2026-02-17 |
| 2023-09-30 | -$90.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$168.20M derived: sum of 2 quarters · filed 2024-11-12 | -$108.31M 10-Q · filed 2024-11-12 | -$79.90M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$77.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$17.78M 10-Q · filed 2024-08-06 | $10.63M derived: sum of 3 quarters · filed 2025-02-25 | -$140.91M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $59.88M 10-Q · filed 2024-05-07 | $88.30M derived: sum of 2 quarters · filed 2025-02-25 | -$63.25M derived: sum of 3 quarters · filed 2025-02-25 | -$64.39M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $28.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$123.13M derived: sum of 2 quarters · filed 2025-02-25 | -$124.28M derived: sum of 3 quarters · filed 2025-02-25 | -$124.72M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$151.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$152.69M derived: sum of 2 quarters · filed 2023-11-07 | -$153.13M 10-Q · filed 2023-11-07 | -$153.56M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$1.58M 10-Q · filed 2023-08-08 | -$2.02M derived: sum of 3 quarters · filed 2024-02-26 | -$3.18M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$441.00K 10-Q · filed 2023-05-09 | -$874.00K derived: sum of 2 quarters · filed 2024-02-26 | -$2.04M derived: sum of 3 quarters · filed 2024-02-26 | |
| 2021-12-31 | -$433.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$1.60M derived: sum of 2 quarters · filed 2024-02-26 | -$1.72M 10-K · filed 2024-02-26 | |
| 2021-09-30 | -$1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$1.29M 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | -$123.00K 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $8.42M 10-K · filed 2022-03-15 | ||
| 2020-09-30 | $8.42M 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $213.00K derived: sum of 2 quarters · filed 2021-03-16 | $8.21M derived: sum of 3 quarters · filed 2021-03-16 | $23.16M 10-K · filed 2021-03-16 |
| 2019-09-30 | $226.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $8.22M derived: sum of 2 quarters · filed 2020-11-09 | $23.17M 10-Q · filed 2020-11-09 | $38.17M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $22.95M 10-Q · filed 2020-08-11 | $37.95M derived: sum of 3 quarters · filed 2020-08-11 | $47.86M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | $14.95M 10-Q · filed 2020-05-11 | $29.95M derived: sum of 2 quarters · filed 2020-05-11 | $39.86M derived: sum of 3 quarters · filed 2020-05-11 | -$1.51M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $24.91M derived: sum of 2 quarters · filed 2020-03-26 | -$16.46M derived: sum of 3 quarters · filed 2020-03-26 | -$10.53M 10-K · filed 2020-03-26 |
| 2018-09-30 | $9.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$31.46M derived: sum of 2 quarters · filed 2019-11-12 | -$25.53M 10-Q · filed 2019-11-12 | -$20.63M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | -$41.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | -$35.45M 10-Q · filed 2019-08-12 | -$30.55M derived: sum of 3 quarters · filed 2019-08-12 | -$24.82M derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | $5.92M 10-Q · filed 2019-05-13 | $10.82M derived: sum of 2 quarters · filed 2019-05-13 | $16.55M derived: sum of 3 quarters · filed 2019-05-13 | |
| 2017-12-31 | $4.90M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | $10.63M derived: sum of 2 quarters · filed 2019-03-28 | $13.59M 10-K · filed 2019-03-28 | |
| 2017-09-30 | $5.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $8.69M 10-Q · filed 2018-11-13 | ||
| 2017-06-30 | $2.96M 10-Q · filed 2018-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |